Rabeprazole
Based on 5 publication(s) in Google Scholar
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.
For research use only. We do not sell to patients.
- Purity: 99.14%
- CAS No.: 117976-89-3
- Formula: C18H21N3O3S
- Molecular Weight:359.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Nephrotoxicity Compound Library
HY-L229
Publications Citing Use of MedChemExpress (MCE) Rabeprazole
More
Biological Activity
Pump inhibitor (PPI)[1]
IC50: 0.3 μM (UNH)[1]
H+/K+-ATPase[2]
Apoptosis[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | IC50 |
7.88 μM
Compound: Rabeprazole
|
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
|
[PMID: 25513712] |
| HEK-293T | IC50 |
4.47 μM
Compound: Rabeprazole
|
Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis
Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis
|
[PMID: 28512024] |
| HUVEC | GI50 |
>100 μM
Compound: Rabeprazole
|
Cytotoxicity against HUVEC cells
Cytotoxicity against HUVEC cells
|
[PMID: 31923859] |
| K562 | GI50 |
>100 μM
Compound: Rabeprazole
|
Antiproliferative activity against human K562 cells harboring MLL1
Antiproliferative activity against human K562 cells harboring MLL1
|
[PMID: 31923859] |
| L02 | GI50 |
>100 μM
Compound: Rabeprazole
|
Cytotoxicity against human L02 cells
Cytotoxicity against human L02 cells
|
[PMID: 31923859] |
| MOLM-13 | GI50 |
17.5 μM
Compound: Rabeprazole
|
Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9
Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9
|
[PMID: 31923859] |
| MV4-11 | GI50 |
14.1 μM
Compound: Rabeprazole
|
Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4
Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4
|
[PMID: 31923859] |
Rabeprazole attenuates the cell viability of the human gastric cancer cells following treatment with 0.2 mM for 16 hours[2].
Rabeprazole completely inhibits the phosphorylation of ERK1/2 in the MKN-28 cells. The gastric cancer cell line MKN-28 is cultured in acidic culture media (pH 5.4) for 2 hours. Pretreatment with Rabeprazole (0.2 mM for 2 hours) leads to strong inhibition of ERK1/2 phosphorylation in the MKN-28 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Three gastric cancer cell lines KATO III, MKN-28 and MKN-45
-
Concentration:0.2 mM
-
Incubation Time:16 hours
-
Result:Treatment resulted in the attenuation of viability in all cancer cell lines tested, the cell viability of the MKN-28 cells significantly decreased compared with the KATO III and MKN-45 cells, respectively.
-
Cell Line:Three gastric cancer cell lines (KATO III, MKN-28 and MKN-45)[2]
-
Concentration:0.2 mM
-
Incubation Time:Pretreatment for 2 hours
-
Result:Led to strong inhibition of ERK 1/2 phosphorylation in the MKN-28 cells, but a similar effect was not observed in the KATO III and MKN-45 cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Swiss albino mice (body weight equals 18-26 g)[3]
-
Dosage:10 mg/kg
-
Administration:Oral administration; every 48 h for 18 weeks
-
Result:Showed significantly lower serum calcium level compared to the vehicle treated group (5.5±2.07 vs. 9.68±2.77).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 117976-89-3
-
Appearance Solid
-
Molecular Weight 359.44
-
Formula C18H21N3O3S
-
Color Light green to green
-
SMILES
O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCCCOC)=C3C
-
Synonyms
LY307640
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2023 Jul 14;14(1):4217. PMID: 37452028 -
Front Immunol
Candidate Drugs Screening for Behcet's Disease Based on Bioinformatics Analysis and Mouse Experiments. [Abstract]2022 Jun 21;13:895869. PMID: 35799784 -
-
Sci Rep
2026 Mar 20;16(1):14300. PMID: 41862552 -
Biomed Rep
2025 Dec 4;24(2):25. PMID: 41425655
Solvent & Solubility
DMSO : 19.44 mg/mL (54.08 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tara A Shea, et al. Identification of Proton-Pump Inhibitor Drugs That Inhibit Trichomonas Vaginalis Uridine Nucleoside Ribohydrolase. Bioorg Med Chem Lett. 2014 Feb 15;24(4):1080-4. [Content Brief]
[2]. Mengli Gu, et al. Rabeprazole Exhibits Antiproliferative Effects on Human Gastric Cancer Cell Lines. Oncol Lett. 2014 Oct;8(4):1739-1744. [Content Brief]
[3]. Aly A M Shaalan, et al. Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels. Front Pharmacol. 2020 May 13;11:583. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7821 mL | 13.9105 mL | 27.8211 mL | 69.5526 mL |
| 5 mM | 0.5564 mL | 2.7821 mL | 5.5642 mL | 13.9105 mL | |
| 10 mM | 0.2782 mL | 1.3911 mL | 2.7821 mL | 6.9553 mL | |
| 15 mM | 0.1855 mL | 0.9274 mL | 1.8547 mL | 4.6368 mL | |
| 20 mM | 0.1391 mL | 0.6955 mL | 1.3911 mL | 3.4776 mL | |
| 25 mM | 0.1113 mL | 0.5564 mL | 1.1128 mL | 2.7821 mL | |
| 30 mM | 0.0927 mL | 0.4637 mL | 0.9274 mL | 2.3184 mL | |
| 40 mM | 0.0696 mL | 0.3478 mL | 0.6955 mL | 1.7388 mL | |
| 50 mM | 0.0556 mL | 0.2782 mL | 0.5564 mL | 1.3911 mL |
Powered by Bioz